Pneumonia (labelled as an SAE) · stable COPD
Triple therapy probably leads to higher pneumonia (labelled as an SAE) compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
SAEs · stable COPD
Triple therapy showed no clear difference in all‐cause SAEs compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Symptoms of dyspnoea · stable COPD
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · stable COPD
Triple therapy may leads to higher lung function, change in trough FEV1 (mL) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Pulmonary exacerbations · adults (aged 16 years and over) with CF
Digital technology (web‐based platform CFHealthHub) probably leads to lower number of pulmonary exacerbations compared with usual care (moderate certainty).
1 finding from 1 review
Treatment burden · children aged 5 to 16 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · children aged 5 to 16 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 (% predicted): mean change from baseline · children aged 5 to 16 years
Digital technology (TIM) showed no clear difference in FEV1 (mean change from baseline, % predicted) compared with standard treatment (TBM) (low certainty).
1 finding from 1 review
Pulmonary exacerbations · children aged 5 to 16 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment burden · adults (aged 16 years and over) with CF
Digital technology (web‐based platform CFHealthHub) probably leads to higher treatment burden: CFQ‐R treatment burden domain score (higher score… compared with usual care (moderate certainty).
1 finding from 1 review
QoL · adults (aged 16 years and over) with CF
Digital technology (web‐based platform CFHealthHub) showed no clear difference in qoL: CFQ‐R domain scores at end of study compared with usual care (moderate certainty).
1 finding from 1 review
FEV1 % predicted · adults (aged 16 years and over) with CF
Digital technology (web‐based platform CFHealthHub) showed no clear difference in FEV1: mean FEV1 % predicted at end of study compared with usual care (low certainty).
1 finding from 1 review
QoL · adults (aged 16 years and over) with CF
1 finding from 1 review
FEV1 % predicted · adults (aged 16 years and over) with CF
1 finding from 1 review
Pulmonary exacerbations · adults (aged 16 years and over) with CF
1 finding from 1 review
Treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) · children, adolescents or adults with CF
Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) compared with usual care (low certainty).
1 finding from 1 review
Treatment‐related adverse events Depression PHQ‐8 (Kroenke 2009) · children, adolescents or adults with CF
Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Depression PHQ‐8 (Kroenke 2009) compared with usual care (low certainty).
1 finding from 1 review
QoL · children, adolescents or adults with CF
Summary of findings: psychological interventions may leads to higher qoL CFQ‐R (Quittner 2009) compared with usual care (low certainty).
1 finding from 1 review
FEV1 % predicted · children, adolescents or adults with CF
Summary of findings: psychological interventions showed no clear difference in lung function FEV1 % predicted compared with usual care (moderate certainty).
1 finding from 1 review